Johnson & Johnson Struggling

Discussion in 'Johnson & Johnson' started by anonymous, May 14, 2023 at 4:01 AM.

Tags: Add Tags
  1. anonymous2

    anonymous2 Guest

    After the next few performance results this year..we’ll have a better idea of medtech future in JNJ…don’t let them fool you..Pharma and Medtech don’t work together in todays market
     

  2. anonymous

    anonymous Guest

    Duato already said he wants JNJ to be a pharma company with robotics to help with drug delivery. The rest of medical devices will have to be spun-off or divested.

    Look at the Abbott-AbbVie split that took place in 2013. That will be the next step for JNJ.

    DePuy Synthes, Ethicon, Vision, Abiomed, BWI, & the rest of the JNJ med device opcos will have to be separated either together or in pieces, while pharma & some sort of drug delivery/robotics piece gets grouped together.

    Perhaps the medical device piece keeps the JNJ corporate name, while Janssen gets separated as a pharma company? When Abbott split in 2013, the pharma piece was spun-off as AbbVie while all the med device & diagnostic businesses remained with Abbott.
     
  3. anonymous5

    anonymous5 Guest

    Agree with the comment above…JD already said his plan is to be a “Pharma” type sector . The garage sale of Medtech will be in 2026.
     
  4. anonymous

    anonymous Guest

    The garage sale has been on-going for a decade already. Ortho Clinical Diagnostics, Cordis, Lifescan, Codman, ASP, and Calibra have already been sold.

    OCD, Cordis, and Lifescan used to be the bread and butter of the JNJ medical device segment.

    There's already rumors that JNJ is actively-shopping Mentor to private equity firms.

    After the Kenvue separation is largely completed this year, I expect JNJ to proceed with plans to have an IPO for Janssen in 2024 or 2025.
     
  5. anonymous

    anonymous Guest

    Mentor is small and isn’t worth holding onto. Wouldn’t be surprised it’s being presented to PE.
     
  6. anonymous

    anonymous Guest

    Mentor is a great example of how quickly the company can either miss completely on an acquisition or screw it to hell after the acquisition. Add to the list Synthes, Acclarent, Auris.
     
  7. anonymous

    anonymous Guest

    J&J Medtech have been in slow decline for a decade, it's not just the lack of innovation, it's activist HR policies that rotate leaders around every 3-5 years preventing them from forming real customer relationships or being held accountable for their decisions
    Talent with actual clinical and customer focus are gaslighted as being a "domain experts" rather than an "agile enterprise leaders"

    On top a zealous Health Care Compliance function that acts like the Spanish Inquisition and treats employees as guilty until proven innocent.
    Customer facing leaders and Field teams are too scared to do what they need to do compete in the market especially in clinical education which has been detached from commercial reality.
    As a Sales Manager, Marketer, or Rep it's safer and easier to do nothing that involves healthcare compliance and hope the share loss on their watch is not so noticeable vs running the risks of a career ending compliance audit.
    J&J's surgeon customers have shifted to competitors that are commercially driven and happy to compete for market share and build actual relationships with them without a holier than thou compliance team inserting themselves into everything.
    Surgeons know their value and their power and are insulted to be lectured on ethics to by any company, especially one with it's own dirty linen.
     
  8. anonymous

    anonymous Guest

    Exodus will start in 2025, because 2025 is the last year of the FAP traditional pension plan. So many folks aged 55-62 will leave. I believe, in fact hundreds will leave. But it is anticipated and planned for.
     
  9. anonymous

    anonymous Guest

    Why did they get rid of OCD, Cordis and Lifescan if they were bread and butter?
     
  10. anonymous

    anonymous Guest

    J&J wants them to leave, like 10,000 of them. Don’t do it voluntarily. They will put pressure on you to leave. Stick it out, don’t leave without a severance package.
     
  11. anonymous

    anonymous Guest

    Are any big surprises coming in June across pharma and medtech?
     
  12. anonymous

    anonymous Guest

    Yes
     
  13. anonymous

    anonymous Guest

    yes, more cuts in June & September, sorry to say
     
  14. anonymous

    anonymous Guest

    Where? What division, country, opco, etc.... If you truly know something the spill it and don't be so cryptic.
     
  15. anonymous

    anonymous Guest

    Should be some job openings in PH in a few weeks
     
  16. anonymous

    anonymous Guest

    Should be some openings in PH in a few weeks
     
  17. anonymous

    anonymous Guest

    cryptic? the poster willingly provided dates, do you want names, too?

    on this board people provide free information of their choosing, so If you don’t want the information, then stop reading the posts, LOL

    entitled little brat, I hope you are first on the list, so get back to work.
     
  18. anonymous

    anonymous Guest

    Gayet advice from a musical jnj automaton QUOTE="anonymous, post: 6788630"]cryptic? the poster willingly provided dates, do you want names, too?

    on this board people provide free information of their choosing, so If you don’t want the information, then stop reading the posts, LOL

    entitled little brat, I hope you are first on the list, so get back to work.[/QUOTE]
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest

    JNJ doesnt care about performance.... all they care about is DEI. How many other device companies have leadership teams that are made up of 100% females? Or 100% african americans? Only at JnJ